SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-26 and is reviewed periodically as new material appears.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
== Dietary supplement == Although neither a prescription drug nor an essential nutrient, CoQ10 is commonly used as a dietary supplement with the intent to prevent or improve disease conditions, such as cardiovascular disorders. Despite its significant role in the body, it is not used as a drug to treat any specific disease. Nevertheless, CoQ10 is widely available as an over-the-counter dietary supplement and is recommended by some healthcare professionals, despite a lack of definitive scientific evidence supporting these recommendations, especially when it comes to cardiovascular diseases.
Intein-containing Prp8 is most commonly found in fungi, but is also seen in Amoebozoa, Chlorophyta, Capsaspora, and Choanoflagellida. Many mycobacteria contain inteins within DnaB (bacterial replicative helicase), RecA (bacterial DNA recombinase), and SufB (FeS cluster assembly protein). There is remarkable variety within the structure and number of DnaB inteins, both within the mycobacterium genus and beyond. Interestingly, intein-containing DnaB is also found in the chloroplasts of algae. Intein-containing proteins found in archaea include RadA (RecA homolog), RFC, PolB, RNR. Many of the same intein-containing proteins (or their homologs) are found in two or even all three domains of life. Inteins are also seen in the proteomes encoded by bacteriophages and eukaryotic viruses. Viruses may have been involved as vectors of intein distribution across the wide variety of intein containing organisms.
=== China === The first consignments of the a2 Milk Company infant formula – a2 Platinum were sent to China in 2013. Exports to China have increased dramatically following the 2008 Chinese milk scandal.
== P == Paracelsus (1493–1541), alchemist Rudolph Pariser (1923–2021), theoretical and organic chemist Robert G. Parr (1921–2017), theoretical chemist Louis Pasteur (1822–1895), French biochemist, father of pasteurization Linus Pauling (1901–1994), Nobel Prizes in chemistry and peace Charles J. Pedersen (1904–1989), 1987 Nobel Prize in Chemistry Eugène-Melchior Péligot (1811–1890), French chemist who isolated the uranium metal William Henry Perkin (1838–1907), British organic chemist and inventor of mauveine (dye) William Henry Perkin, Jr. (1860–1929), British organic chemist, son of Sir William Henry Perkin Max Perutz (1914–2002), 1962 Nobel Prize in Chemistry Eva Philbin (1914–2005), Irish chemist David Andrew Phoenix (born 1966), British biochemist Georgy Pigulevsky (1888–1964), Russian chemist and biochemist James Pitts (1921–2014), American chemist known for work on photochemistry and atmospheric chemistry Roy J. Plunkett (1910–1994), discoverer of Teflon John Charles Polanyi (born 1929), Canadian chemist, Nobel Prize in Chemistry 1986 John A.
Inhalation of environmental and occupational pollutants, such as metals in asbestosis, silicosis, and exposure to certain gases. Coal miners, ship workers and sand blasters, among others, are at higher risk. Hypersensitivity pneumonitis, most often resulting from inhaling dust contaminated with bacterial, fungal, or animal products Cigarette smoking can increase the risk or make the illness worse. Smoking is a known cause of some types of lung fibrosis, such as smoking-related interstitial fibrosis (SRIF). Some typical connective tissue diseases such as rheumatoid arthritis, ankylosing spondylitis, SLE and scleroderma Other diseases that involve connective tissue, such as sarcoidosis and granulomatosis with polyangiitis Infections, including COVID-19 Certain medications, e.g. amiodarone, bleomycin (pingyangmycin), busulfan, apomorphine, and nitrofurantoin Radiation therapy to the chest
Sources: en.wikipedia.org
== History == Creatine was first identified in 1832 when Michel Eugène Chevreul isolated the precipitate from the basified water-extract of skeletal muscle. He later named the crystallized precipitate after the Greek word for meat, κρέας (kreas). In 1928, creatine was shown to exist in equilibrium with creatinine. Studies in the 1920s showed that consumption of large amounts of creatine did not result in its excretion. This result pointed to the ability of the body to store creatine, which in turn suggested its use as a dietary supplement. In 1912, Harvard University researchers Otto Folin and Willey Glover Denis found evidence that ingesting creatine can dramatically boost the creatine content of the muscle. The discovery of phosphocreatine was reported in 1927. In the 1960s, the enzyme creatine kinase was shown to phosphorylate ADP using phosphocreatine to generate ATP and thus buffering the ATP/ADP ratio. While creatine's influence on physical performance has been well documented since the early twentieth century, it came into public view following the 1992 Olympics in Barcelona. An 7 August 1992 article in The Times reported that Linford Christie, the gold medal winner at 100 metres, had used creatine before the Olympics. An article in Bodybuilding Monthly named Sally Gunnell, who was the gold medalist in the 400-metre hurdles, as another creatine user. In addition, The Times also noted that 110 metre hurdler Colin Jackson began taking creatine before the Olympics.
Oxaloacetate to malate, using NADH + H+ Oxaloacetate + NADH/H+ → Malate + NAD+ Fumarate to succinate, catalyzed by an oxidoreductase, Fumarate reductase Fumarate + FADH2 ⇌ Succinate + FAD Succinate to succinyl-CoA, an ATP-dependent step Succinate + ATP + CoA → Succinyl-CoA + ADP + Pi Succinyl-CoA to alpha-ketoglutarate, using one molecule of CO2 Succinyl-CoA + CO2 + Fd(red) → alpha-ketoglutarate + Fd(ox) Alpha-ketoglutarate to isocitrate, using NADPH + H+ and another molecule of CO2 Alpha-ketoglutarate + CO2 + NAD(P)H/H+ → Isocitrate + NAD(P)+ Citrate converted into oxaloacetate and acetyl-CoA, this is an ATP dependent step and the key enzyme is the ATP citrate lyase Citrate + ATP + CoA → Oxaloacetate + Acetyl-CoA + ADP + Pi This pathway is cyclic due to the regeneration of the oxaloacetate. The bacteria Gammaproteobacteria and Riftia pachyptila switch from the Calvin-Benson cycle to the rTCA cycle in response to concentrations of H2S.
The small vessels in the skin affected are located in the superficial dermis and include arterioles (small arteries carrying blood to capillaries), capillaries, and venules (small veins receiving blood from capillaries). In general, immune complexes deposit in vessel walls leading to activation of the complement system. C3a and C5a, proteins produced from the complement system, attract neutrophils to the vessels. Once activated, neutrophils then release preformed substances, including enzymes, causing damage to vessel tissue. Evidence of this process can be seen with a sample of removed skin tissue, or biopsy, viewed under a microscope. Neutrophils are seen surrounding blood vessels and their debris within vessel walls, causing fibrinoid necrosis. This finding on histological examination is termed "leukocytoclastic vasculitis". Considering the wide range of potential causes leading to cutaneous small vessel vasculitis, there are subtle variations in the underlying pathophysiology for each cause. For example, medications are metabolized to smaller molecules that can attach to proteins in the blood or vessel walls. The immune system senses these altered proteins as foreign and produces antibodies in efforts to eliminate them from the body. A similar process occurs with infectious agents, such as bacteria, in which antibodies target microbial components.
== Clinical significance == There are many diseases where failure to adequately absorb iron contributes to iron deficiency and iron deficiency anemia. The treatment will depend on the hepcidin levels that are present, as oral treatment will be unlikely to be effective if hepcidin is blocking enteral absorption; in these cases, parenteral iron treatment would be appropriate. Studies have found that measuring hepcidin would help establish the optimal treatment for a patient, but as this is not widely available, C-reactive protein (CRP) is used as a surrogate marker. Chronic alcohol consumption can lead to excess iron accumulation in the liver, which may contribute to the development of alcoholic liver disease. Chronic alcohol use may increase iron accumulation by inhibiting hepcidin gene expression. The main mechanisms appear to be increasing oxidative stress through its metabolite acetaldehyde, and by inhibiting the release of interleukin 6 (IL-6) from macrophages; each of these actions reduce the expression and DNA-binding activity of the transcription factor C/EBPα, which would otherwise stimulate hepcidin expression. Beta thalassemia, one of the most common congenital anemias, arises from partial or complete failure to synthesize beta-globin, a component of hemoglobin. Excessive iron absorption is one of the main features of beta thalassemia and can lead to severe morbidity and mortality.
Sources: en.wikipedia.org
== Gaiden 1 == The Gaiden 1 (外伝1) series, released between February and September 1998, adapts the short stories "Silver-White Valley" (episodes 1–4), "Dreams of the Morning, Songs of the Night" (5–8), "Dishonour", and the novel A Hundred Billion Stars, a Hundred Billion Lights (9–12). Both Gaidens are prequels to the main story, depicting events that take place before season 1 of the show.
=== UK === The UK site is provided by the Association for Laboratory Medicine. It provides contextual hyperlinks from individual reports to the appropriate support information on the site. This is in routine use from one of the major suppliers of clinical informations systems in primary care and from the English NHS app.
== Hazards == Bottles of di-tert-butyl dicarbonate buildup of internal pressure in sealed containers caused by its slow decomposition to di-tert-butyl carbonate and ultimately tert-butanol and CO2 in the presence of moisture. For this reason, it is usually sold and stored in plastic bottles rather than glass ones. The main hazard of the reagent is its inhalational toxicity. Its median lethal concentration of 100 mg/m3 over 4 hours in rats is comparable to that of phosgene (49 mg/m3 over 50 min in rats).
=== Calcification and lipids === Calcification forms among vascular smooth muscle cells of the surrounding muscular layer, specifically in the muscle cells adjacent to atheromas and on the surface of atheroma plaques and tissue. In time, as cells die, this leads to extracellular calcium deposits between the muscular wall and outer portion of the atheromatous plaques. With the atheromatous plaque interfering with the regulation of calcium deposition, it accumulates and crystallizes. A similar form of intramural calcification, presenting the picture of an early phase of arteriosclerosis, appears to be induced by many drugs with an antiproliferative mechanism of action (Rainer Liedtke 2008). Cholesterol is delivered into the vessel wall by cholesterol-containing low-density lipoprotein (LDL) particles. To attract and stimulate macrophages, the cholesterol must be released from the LDL particles and oxidized, a key step in the ongoing inflammatory process. The process is worsened if there is insufficient high-density lipoprotein (HDL), the lipoprotein particle that removes cholesterol from tissues and carries it back to the liver. The foam cells and platelets encourage the migration and proliferation of smooth muscle cells, which in turn ingest lipids, become replaced by collagen, and transform into foam cells themselves. A protective fibrous cap normally forms between the fatty deposits and the artery lining (the intima). These capped fatty deposits (now called 'atheromas') produce enzymes that cause the artery to enlarge over time.
Scurvy or scorbutus is a deficiency disease (state of malnutrition) resulting from a lack of vitamin C (ascorbic acid). Early symptoms of deficiency include weakness, fatigue, and sore arms and legs. Without treatment, decreased red blood cells, gum disease, changes to hair, and bleeding from the skin may occur. As scurvy worsens, there can be poor wound healing, personality changes, and finally death from infection or bleeding. It takes at least a month of little to no vitamin C in the diet before symptoms occur. In modern times, scurvy occurs most commonly in neglected children, people with mental disorders, unusual eating habits such as ARFID, alcoholism, and older people who live alone. Other risk factors include intestinal malabsorption and dialysis. While almost all animals, plants, and other life forms produce their vitamin C, humans and a few others do not. Vitamin C, an antioxidant, is required to make the building blocks for collagen, carnitine, and catecholamines, and assists the intestines in the absorption of iron from foods. Diagnosis is typically based on outward appearance, X-rays, and improvement after treatment. Treatment is with vitamin C supplements taken by mouth, or intravenously for optimal resolution. Improvement often begins in a few days with complete recovery in a few weeks. Sources of vitamin C in the diet include raw citrus fruit and several raw vegetables, including red peppers, broccoli, and tomatoes. Cooking often decreases the residual amount of vitamin C in foods. Scurvy is rare compared to other nutritional deficiencies.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.